
Patients with PD-L1-negative non-small cell lung cancer experienced longer progression-free survival with sac-TMT plus Keytruda compared with chemotherapy plus Keytruda in a phase 3 trial.
Celebratory gala recognizes patient advocates, clinicians, communicators and a research foundation for improving the lives of people living with rare blood cancers.
Orlando, Fla. (PRWEB) December 04, 2015 -- Tonight the spotlight is on eight honorees who serve the MPN community as patient advocates, clinicians, communicators and a research foundation as CURE






